Evidence map›Paper›PMID 40465065›Full record

ArticleMolecular neurobiology2025

The Inhibition of Fatty Acid Amide Hydrolase-4 Affords Neuroprotection in a Toxic Model Induced by 6-Hydroxydopamine in Caenorhabditis elegans Nematodes.

Rubén Estrada-Valencia, Isaac Túnez, Alexey A Tinkov, Michael Aschner, Tessy López-Goerne, José Pedraza-Chaverrí, Abel Santamaría

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rubén Estrada-ValenciaPrograma de Posgrado (Maestría) en Ciencias Biológicas, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico.
Isaac TúnezDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermeria, Universidad de Córdoba/Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, 14071, Spain.
Alexey A TinkovCenter of Bioelementology and Human Ecology, IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119146, Russia.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Tessy López-GoerneLaboratorio de Nanotecnología y Nanomedicina, Departamento de Atención a La Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, 04960, Mexico.
José Pedraza-ChaverríLaboratorio F-315, Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, 04510, Mexico.
Abel SantamaríaLaboratorio de Nanotecnología y Nanomedicina, Departamento de Atención a La Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, 04960, Mexico. absada@yahoo.com.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías 830282DGAPA, UNAM IN202725NIEHS NIH HHS R01ES03771
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons. Drugs modulating the endocannabinoid system (ECS) emerge as promising tools for reducing symptomatology and/or progression of this disease. Here, the protective potential of ECS regulation against 6-hydroxydopamine (6-OHDA)-induced neuronal damage was evaluated in the nematode, Caenorhabditis elegans. First, the effect of the endocannabinoid anandamide (AEA; 1 to 100 µM) was tested in adult nematodes. As this eCB had no protective effects on the 6-OHDA-induced increased neurodegeneration, an alternative treatment was tested by exposing worms to JZL184, an inhibitor of the enzyme fatty acid amide hydrolase-4 (FAAH-4). In contrast to AEA, this compound readily induced a protective effect in dopaminergic neurons exposed to 6-OHDA, also increasing worm survival. JZL184 also improved the ability of nematodes to detect food, a behavioral task associated with an intact dopaminergic system. The protective activity induced by FAAH-4 inhibition was also confirmed using the mutant OD3609 strain, a faah-4 gene knockout nematode. This strain was more resistant to 6-OHDA compared to the wild-type N2 strain, in parameters of survival and food seeking behavior. In the CL2166 strain, pretreatment with JZL184 increased the expression of the gst-4 gene at 3 and 24 h following the exposure to 6-OHDA, indicating an antioxidant response. The effects of JZL184 (50 µM) and the endocannabinoid 2-arachidonoylglycerol (2-AG; 1-100 µM) were evaluated on 6-OHDA-induced reactive oxygen species (ROS) generation. This was based on the hypothesis that the protective effects observed following FAAH-4 inhibition may be mediated by 2-AG. Both JZL-184 and 2-AG attenuated ROS formation 24 h after 6-OHDA exposure. Altogether, these results suggest that the use of the pharmacological inhibitor of eCB degradation is effective in affording neuroprotection, also indicating that the activation of antioxidant responses mediated by the ECS is a process conserved through the evolution in the nematode.

Indexed as

EndocannabinoidsFatty Acid Amide HydrolasesNeuroprotective AgentsParkinson Disease, SecondaryAnimalsAnimals, Genetically ModifiedArachidonic AcidsBenzodioxolesCaenorhabditis elegansCaenorhabditis elegans ProteinsDisease Models, AnimalDopaminergic NeuronsGene Knockout TechniquesGlutathione TransferaseGlyceridesOxidopamineanandamideArachidonic AcidsBenzodioxolesCaenorhabditis elegans ProteinsEndocannabinoidsFatty Acid Amide HydrolasesGlutathione TransferaseGlyceridesglyceryl 2-arachidonategst-4 protein, C elegansJZL 184Neuroprotective AgentsOxidopaminePiperidinesPolyunsaturated AlkamidesReactive Oxygen Species6-HydroxydopamineCannabinoid systemC. elegansFAAH-4JZL184NeuroprotectionNeurotoxicity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.